[July 8-10, 2009]
Rio de Janeiro, Brazil
A three-day international symposium organised by Fiocruz to celebrate the 100 years of Chagas disease discovery by Brazilian researcher, Carlos Chagas, gathered more than 750 international experts. Speakers from five South American countries – together with speakers from France, Canada and the US, including Institut Pasteur, MSF, and DNDi – covered many aspects of Chagas disease: its history, epidemiology, vector control, molecular biology, immunology, and clinical treatment. In parallel to this event, on July 09, DNDi and MSF launched the Chagas Campaign to raise awareness that more is needed to fight the disease: www.treatchagas.org
[July 8-10, 2009]
[July 6-9, 2009]
Geneva, Switzerland DNDi participated at ECOSOC’s Innovation Fair at the High-Level Segment meeting, which took place in Geneva. This meeting and all the “satellite” activities presented good opportunities to discuss research & development issues, especially in the neglected diseases sector. DNDi had a booth at ECOSOC’s Innovation Fair and made a presentation about the Leishmaniasis East Africa Platform (LEAP)
[June 24, 2009]
How to Strengthen Capacity in Africa for the Registration of New Drugs for Neglected Diseases? That was the topic discussed by more than 50 attendees at the workshop which was held during DNDi‘s 2nd Stakeholders’ and 3rd African Meetings, in Nairobi, Kenya.
[ June 23, 2009 ]
Like last year in New York, Drugs for Neglected Diseases initiative (DNDi) will bring together more than 150 scientists, researchers, academics and global health leaders from Africa, Asia, Europe, Latin America and North America on June 23, 2009, to discuss how international research partnerships can best develop and deliver new lifesaving drugs for neglected diseases.
[ May 18-21, 2009 ]
DNDi and iOWH hoeld panel sessions at BIO 2009.
[ February 23, 2009 ]
New York, USA
[February 3-7, 2009]
Every 4 years, leishmaniasis experts gather together from around the world. During World Leish 4, DNDi held 2 symposia on “partnering along the path to deliver better treatments”.
[ December 7-11, 2008 ]
New Orleans, USA
DNDi sponsored a HAT Symposium: “Addressing R&D challenges in making new drugs available for HAT: potential in the pipeline and recent clinical results”, including presentations on HAT platform, NECT, fexinidazole, and DB289.
[ October 13, 2008 ]
New Delhi, India
More than 100 scientists and researchers convened in New Delhi to discuss the present and future role of India in research and development (R&D), access, and capacity strengthening to develop and deliver new treatments needed by neglected patients.
[ June 2008 ]
Leading researchers from research institutes in Asia, DNDi, and MMV met from 9th-11th June to share their vision to make Asia a major player in drug development for the neglected diseases, utilizing local natural resources. This meeting of PAN4ND was co-hosted by DNDi and the Kitasato Institute.
[ June 26, 2008 ]
New York, USA
DNDi’s First Stakeholders’ meeting took place on 26th June in New York and brought together 150 scientists, researchers, academics, and global health leaders from 25 countries to discuss how international research partnerships can best develop and deliver new lifesaving drugs for neglected diseases.
[ April 2008 ]
Rio de Janeiro, Brazil
Farmanguinhos/Fiocruz and DNDi launched ASMQ, the new fixed-dose combination of artesunate (AS) and mefloquine (MQ), now registered in Brazil. Developed and delivered by a worldwide collaboration of public partners, ASMQ will soon be available throughout Latin American and Southeast Asia.
[ February 2008 ]
The 10th Leishmaniasis East Africa Platform (LEAP) meeting took place in Khartoum, Sudan. A solid clinical trial network is being built, thanks to the serious commitment of all members. Capacity building is still ongoing, with one site in Kenya to be built and another in Uganda to be strengthened. In May 2008, DNDi and its partners inaugurated a new treatment centre in Gondar, Ethiopia, with a 24 bed capacity.
[ November 2007 ]
Sanofi-aventis and DNDi held a symposium on the implementation of a new artemisinin combination therapy (ACT) in African endemic countries. Over 120 attendees from NGOs, academia, and the pharmaceutical sector heard presentations by FACT project partners on ASAQ and ASMQ. In addition, DNDi also presented the ethical considerations of malaria field studies, and screening of natural products against infectious disease pathogens.
[ September 2007 ]
DNDi and the Leishmaniasis East Africa Platform (LEAP) organised a scientific symposium on visceral leishmaniasis (VL): “A step together in the right direction” at the centenary meeting of the Royal Society of Tropical Medicine and Hygiene (RSTMH), in London. More than 120 scientists attended the meeting.
[ June 2007 ]
The PAN4ND Annual Meeting was held at Shanghai Institute Materia Medica, 4th-6th June 2007, and included three sessions: The Annual Meeting of the Pan-Asian Screening Network; the Natural Product Working Group, and the Natural Product Symposium.
[ May 2007 ]
Amsterdam, The Netherlands
DNDi, in two presentations, discussed how Product Development Partnerships could deliver innovative treatments to patients, and the sanofi-aventis / DNDi Partnership against malaria, at the 5th ECTMIH from 24 to 28 May in Amsterdam.
[ March 2007 ]
Sanofi-aventis and DNDi launched ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), which is now available in 21 countries throughout sub-Saharan Africa (June 08). ASAQ, the first drug developed by DNDi, is an innovative product to treat malaria that is adapted to the needs of patients of all ages, simple to use, accessible as a non patented drug, and available at an affordable price.
DNDi participated in two symposiums at the ASTMH in Atlanta.
[ September 2006 ]
Over 200 African scientists from 34 countries met in Nairobi, Kenya, 19-23 September at an international conference organised by the Drugs for Neglected Diseases initiative (DNDi), to explore developing greater regional research partnerships to combat the most neglected diseases, such as sleeping sickness, kala azar and malaria.